drugset / Trial / NCT01017770

Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso

NCT01017770

RandomizedParallel-groupOpen-labelTreatment

Summary

Several countries in Africa have changed their first-line treatment for uncomplicated malaria to an ACT. Burkina Faso has changed its policy to Artemether-Lumefantrine (AL) and Artesunate-Amodiaquine (AQ+AS). However, such choice has been done without knowing the local effectiveness of these drugs when they are given to patients in real life conditions, without direct observation of the drug administration. Thus, this study aims at investigating the effectiveness of AQ+AS and AL, when given to children with uncomplicated malaria in Burkina Faso.

Timeline

Start
2008-09
Primary completion
2010-01
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Artemether-lumefantrine Unknown
Subject Artesunate-amodiaquine Unknown 25 mg
Subject Artesunate-amodiaquine Unknown 50 mg
Subject Artesunate-amodiaquine Unknown 67.5 mg
Subject Artesunate-amodiaquine Unknown 100 mg
Subject Artesunate-amodiaquine Unknown 135 mg
Subject Artesunate-amodiaquine Unknown 270 mg